



Patent
Case No.: 57071US040

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: DELLARIA, JR., JOSEPH F
Application No.: 10/696684 Group Art Unit: 1625
Filed: October 29, 2003 Examiner: Huang, Evelyn Mei
Title: THIOETHER SUBSTITUTED IMIDAZOQUINOLINES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

07 January 2004 *Renee A. Wolff*
Date Signed by: Renee A. Wolff

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. Copies of any cited foreign patents, non-patent literature, and unpublished US application documents are enclosed. Pursuant to the waiver in the Pre-OG Notice, dated July 11, 2003, copies of US patents and published US patent applications are no longer required and are not enclosed. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Applicants also wish to bring to the Examiner's attention Parent application 10/013,059 (Patent No. 6,664,264), application 10/165,222 (Patent No. 6,667,312), and the Office Actions therefore.

It is believed that no fee is due; however, in the event a fee is required, please charge the fee to Deposit Account No. 13-3723.

Respectfully submitted,

6 JANUARY 2004
Date

By: *Dean A. Ersfeld*
Dean A. Ersfeld, Reg. No.: 46,689
Telephone No.: (651) 733-7830

Office of Intellectual Property Counsel
3M Innovative Properties Company
Facsimile No.: 651-736-3833

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

Page 1 of 4



U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US- 3,314,941	04-18-1967	Littell et al.	
	A2	US- 4,689,338	08-25-1987	John F. Gerster	
	A3	US- 4,698,348	10-06-1987	John F. Gerster	
	A4	US- 4,929,624	05-29-1990	Gerster et al.	
	A5	US- 4,988,815	01-29-1991	Andre et al.	
	A6	US- 5,037,986	08-06-1991	John F. Gerster	
	A7	US- 5,175,296	12-29-1992	Gerster	
	A8	US- 5,238,944	08-24-1993	Wick et al.	
	A9	US- 5,266,575	11-30-1993	John F. Gerster	
	A10	US- 5,268,376	12-07-1993	John F. Gerster	
	A11	US- 5,346,905	09-13-1994	John F. Gerster	
	A12	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A13	US- 5,367,076	11-22-1994	Gerster	
	A14	US- 5,389,640	02-14-1995	Gerster et al.	
	A15	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A16	US- 5,446,153	08-29-1995	Lindstrom et al.	
	A17	US- 5,482,936	01-09-1996	Kyle J. Lindstrom	
	A18	US- 5,693,811	12-02-1997	Lindstrom	
	A19	US- 5,741,908	04-21-1998	Gerster et al.	
	A20	US- 5,756,747	05-26-1998	Gerster et al.	
	A21	US- 5,939,090	08-17-1999	Beaurline et al.	
	A22	US- 6,039,969	03-21-2000	Tomai et al.	
	A23	US- 6,069,149	05-30-2000	Nanba et al.	
	A24	US- 6,083,505	07-04-2000	Miller et al.	
	A25	US- 6,110,929	08-29-2000	Gerster et al.	
	A26	US- 6,194,425	02-27-2001	Gerster et al.	
	A27	US- 6,245,776	06-12-2002	Skwierczynski et al.	
	A28	US- 6,331,539	12-18-2001	Crooks et al.	

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

Page 2 of 4

Application Number

10/696,684

Filing Date

October 29, 2003

First Named Inventor

Joseph F. Dellaria

Art Unit

Unknown

Examiner Name

Unknown

Attorney Case Number

57071US040

U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A29	US- 6,376,669	04-23-2002	Rice et al.	
	A30	US- 2002/0055517 A1	05-09-2002	Smith	
	A31	US- 2002/0058674 A1	05-16-2002	Hedenstrom et al.	
	A32	US- 6,451,810	09-17-2002	Coleman et al.	
	A33	US- 6,518,265	02-11-2003	Kato et al.	
	A34	US- 6,525,064	02-25-2003	Dellaria et al.	
	A35	US- 6,541,485	04-01-2003	Crooks et al.	
	A36	US- 6,545,016	04-08-2003	Dellaria et al.	
	A37	US- 6,545,017	04-08-2003	Dellaria et al.	
	A38	US- 6,558,951	05-06-2003	Tomai et al.	
	A39	US- 6,573,273	06-03-2003	Crooks et al.	
	A40	US- 6,656,938	12-02-2003	Crooks et al.	
	A41	US- 6,660,735	12-09-2003	Crooks et al.	
	A42	US- 6,664,264	12-16-2003	Dellaria et al.	
	A43	US- 6,664,265	12-16-2003	Crooks et al.	
	A44	US- 6,667,312	12-23-2003	Bonk et al.	

Foreign Patent Documents

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B1	PCT	WO 01/74343	10-11-2001			
	B2	PCT	WO 02/36592	05-10-2002			X
	B3	PCT	WO 02/46188	06-13-2002			
	B4	PCT	WO 02/46189	06-13-2002			
	B5	PCT	WO 02/46190	06-13-2002			
	B6	PCT	WO 02/46193	06-13-2002			
	B7	PCT	WO 02/46749	06-13-2002			
	B8	PCT	WO 02/102377	12-27-2002			
	B9	PCT	WO 03/020889	03-13-2003			

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date

October 29, 2003

First Named Inventor

Joseph F. Dellaria

Art Unit

Unknown

Examiner Name

Unknown

Attorney Case Number

57071US040

Use as many sheets as necessary)

Page 3 of 4

Foreign Patent Documents

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B10	PCT	WO 03/043572	05-30-2003			
	B11	PCT	WO 03/045391	06-05-2003			
	B12	JP	9-208584	08-12-1997			
	B13	JP	9-255926	03-26-1999			X
	B14	JP	11-222432	08-17-1999			X
	B15	JP	2000-247884 (abs)	09-12-2000			X
	B16	EP	0 394 026	10-24-1990			
	B17	EP	1 104 764	06-06-2001			

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	Wozniak, et al, "The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate ^{1,2} . A New and Convenient Amination Method.", <u>Journal of the Royal Netherlands Chemical Society</u> , 102, pp 511-513, December 12, 1983.
	C2	Brennan, et al, "Automated Bioassay of Interferons in Micro-test Plates", <u>Biotechniques</u> , June/July, 78, 1983.
	C3	Testerman, et al., "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", <u>Journal of Leukocyte Biology</u> , Volume 58, pp. 365-372, September 1995.
	C4	Bachman, et al, "Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline", <u>J. Org. Chem.</u> , 15, pp 1278-1284 (1950).
	C5	Jain, et al, "Chemical and Pharmacological Investigations of Some ω -Substituted Alkylamino-3-aminopyridines", <u>J. Med. Chem.</u> , 11, pp 87-92 (1968).
	C6	Baranov, et al., <u>Chem. Abs.</u> 85, 94362, (1976).
	C7	Berényi, et al, "Ring Transformation of Condensed Dihydro-as-triazines", <u>J. Heterocyclic Chem.</u> , 18, pp 1537-1540 (1981).
	C8	Chollet, et al, "Development of a Topically Active Imiquimod Formulation", <u>Pharmaceutical Development and Technology</u> , 4(1), pp 35-43 (1999)
	C9	Izumi, et al., "1H-Imidazo[4,5-c]quinoline Derivatives as Novel Potent TNF- α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1H-imidazo[4,5-c]pyridines", <u>Bioorganic & Medicinal Chemistry</u> , 11, pp 2541-2550 (2003)
	C10	Sidky et al., "Inhibition of Murine Tumor Growth by an Interferon-inducing Imidazoquinolinamine", <u>Cancer Research</u> , 52, 3528-3533, July 1, 1992.

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

Page 4 of 4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C11	R.L. Miller et al., "Imiquimod applied topically: a novel immune response modifier and new class of drug", <u>International Journal of Immunopharmacology</u> , 21, 1-14 (1999).
	C12	Karl R. Beutner, MD, et al., "Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream", <u>J.Am.Acad.Dermatol.</u> , Volume 41, Number 6, 1002-1007 (December 1999).
	C13	Davis et al., "Self-Administered Topical Imiquimod Treatment of Vulvar Intraepithelial Neoplasia", <u>Journal of Reproductive Medicine</u> , Volume 45, Number 8, 619-623, (August 2000).
	C14	Alexander Steinmann et al., "Topical Imiquimod Treatment of a Cutaneous Melanoma Metastasis", <u>J.Am.Acad.Dermatol.</u> , Letters, 555-556 (September 2000).

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.